Impaired interleukin 12 production in human immunodeficiency virus- infected patients by unknown
Brief DeflnRive Report 
Impaired Interleukin  12 Production in Human 
Immunodeficiency  Virus-infected  Patients 
By Jihed Chehimi,* Stuart E. Start,* Ian Frank,~ 
Annalisa D'Andrea,  S Xiaojing Marl Rob Roy MacGregor,~ 
Jerome Sennelier,  II and Giorgio TrinchieriS 
From the *Division of Allergy, Immunology and Infectious Diseases, The Children's Hospital of 
Philadelphia, the *Department of Medicine, The Hospital of the University of Pennsylvania, 
SThe Wistar Institute, Philadelphia, Pennsylvania 19104; and the IIUniversity of Paris VII, 
75005 Paris, France 
Suml'nary 
Peripheral blood mononudear cells (PBMC) from human immunodeficiency  virus (HIV)-infected 
patients, asymptomatic or with acquired immunodeficiency  virus, produced 10-fold less interleukin 
12 (IL-12) flee heavy chain and fivefold less biologically active IL-12 heterodimer than PBMC 
from uninfected healthy donors when challenged in vitro with the common human pathogen 
Staphylococcus aureus. In contrast, PBMC from HIV-infected individuals and uninfected control 
donors produced similar levels of tumor necrosis factor ol, IL-1B, and IL-10, and PBMC from 
HIV-infected individuals produced three- to fourfold more IL-6 compared with PBMC from 
uninfected control donors. The defect in IL-12 production is not due to hyperproduction of 
IL-10, a cytokine exerting an autocrine-negative feedback on IL-12 production, but was directly 
related to HIV infection, as suggested by the reduced ability of monocytes infected in vitro with 
HIV to produce IL-12. IL-12 deficiency may be an important component of the immunodeficiency 
associated with HIV infection. 
p atients with HIV infection at both early or late stages 
have immunoregulatory defects at several levels of the im- 
mune system, and the in vivo progression of the infection 
is closely related to abnormal functioning of the immune 
system (1, 2). The nature and role of the humoral and cell- 
mediated immune responses against HIV have not been fully 
characterized,  and it remains to be established whether im- 
mune responses against HIV prevent primary infection and/or 
protect against disease progression in infected individuals. 
Defining immune responses against HIV that are protective 
is critical for the rational design of effective vaccines and other 
forms of immunotherapy. 
A great deal of information on the role of several cytokines 
during HIV infection has accumulated, although the relative 
extent of their expression remains unclear (1). Natural killer 
cell stimulatory factor (NKSF) or IL-12 is a heterodimeric 
cytokine of 70 kD formed by a H chain (p40) and a L chain 
(p35) encoded by two separate genes (3). IL-12 is produced 
in response to bacteria,  bacterial products, and intracellular 
parasites by cells with accessory or antigen-presenting ability 
(4). When human PBMC are stimulated in vitro, IL-12 is 
mostly produced by monocytes, but, in part, also by B cells, 
and probably by other non-B, nonmonocytic HLA-DR + 
cells (4). Accumulation of p40 mRNA is highly regulated 
and rapidly induced in vitro and in vivo after  stimulation 
of the producer cells with bacteria or bacterial products (4). 
Although only the p70 heterodimer has been shown to have 
biologic activity, the p40 H chain is always produced in large 
excess over the p70 heterodimer, both in vitro (4) and in vivo 
(Wysocka,  M.  and G.  Trinchieri, unpublished results). 
IL-12 has potent and pleomorphic activities  on NK and 
T cells, inducing production of cytokines, particularly IFN-3,, 
enhancement of cytotoxic activity of NK cells (3-5), and gener- 
ation of cytotoxic lymphocytes (6). IL-12 has a proliferative 
effect on T and NK cells, acting synergistically with various 
stimuli, including specific antigen stimulation (7). Both in 
vivo and in vitro, IL-12 is a powerful inducer of T  helper 
cells type I (Thl) responses, whereas it inhibits Th2-type re- 
sponses (8). Emerging evidence indicates  a central role for 
IL-12 in resistance to bacterial and parasitic infections (9, 10). 
In light of its production by phagocytic cells shortly after 
exposure to infectious agents and its powerful effect on the 
regulation of T and NK cell functions, IL-12 represents an 
important link between natural resistance and adaptive im- 
munity (8). 
Because emerging data suggests a relationship between dis- 
ease progression and the nature of the cellular immune re- 
sponse in HIV-infected patients (1, 2, 11), we evaluated the 
ability of HIV-infected patients to produce IL-12 in response 
to bacterial  stimulation. 
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Study Population.  73 consenting  adult patients (22-45-yr-old, 
17 females and 56 males), HIV seropositive and at various stages 
of the disease, were enrolled in this study. HIV serology was deter- 
mined using commercially available assays. All patients were repeat- 
edly positive for HIV antibodies by HIV ELISA, and confirmed 
by Western blot analysis. Patients were classified according to their 
absolute CD4 § cell counts  (<200/ram 3, between 200 and 500/ 
mm 3 higher  than 500/ram3). Healthy  HIV-seronegative donors, 
matched for age and sex, were induded as controls. At the time 
of the study, none of the patients was receiving cytokine therapy. 
Cell Separation.  All reagents used for this study were selected 
for low levels of endotoxin contamination by the Limulus amebo- 
cyte assay. PBMC were separated by Ficoll-Hypaque density gra- 
dient centrifugation  (Lymphoprep; Nygaard and Co., Oslo, Nor- 
way), and resuspended in RPMI-1640 medium supplemented with 
10% heat-inactivated fetal bovine serum (complete medium). Fresh 
monocytes were isolated by incubating  PBMC in plastic flasks at 
37~  for 2 h in ILPMI-1640 supplemented with 20% FCS. Nonad- 
herent cells were removed by several  washes with PBS, and adherent 
cells were incubated for 20 min in ice-cold PBS and resuspended 
at 0.5  x  106 cells/ml.  Adherent  cells were then  incubated  for 
2-3 d before viral infection. These monocyte preparations contained 
>-,90% CD14 § cells, and >~90% nonspecific esterase-positive cells. 
Virus Infection.  HUT-78 and CEM-X174 cell lines were main- 
tained in RPMI-1640 supplemented with 10% FCS (12). Culture 
supernatants of the following HIV-1 strains, displaying a different 
pattern  of cellular tropism,  were used: lymphocyte-tropic  strains 
IIIB and MN, grown in HUT78 cells (provided through the AIDS 
Research and Reference Reagent Program,  RockviUe, MD), and 
monocyte-tropic  stain 89.6 (kindly provided by R. Collman  and 
H. Friedman, University of Pennsylvania) grown in CEM-X174 
cells (12). Virus stocks were titered for p24 core Ag production 
using an Ag capture assay (Coulter Immunology, Hialeah, FL) and 
for tissue culture infective dose. Monocytes (2  x  10  s cells/well) 
were mock infected (with media from the cell lines used to grow 
HIV), or infected with cell-free HIV isolates containing  20-30 
ng/ml of p24 Ag or equivalent amount s of heat-inactivated viruses 
(1 h at 56~  After 3-4 h of incubation at 37~  cells were gently 
washed, resuspended with complete medium, and maintained for 
5-7 d. At the end of the incubation period, culture supernatants 
and cells were harvested for p24 Ag determinations. 
Induction of Cytoh'ne Production.  To induce cytokine production, 
PBMC (2.5  x  106 cells/ml) from seronegative controls and HIV- 
infected individuals were cultured  for 24 h in complete medium 
alone or in the presence of heat-inactivated Staphylococcus aureus 
Cowan strain 1 (Pansorbin; Calbiochem-Behring Corp., La Jolla, 
CA, diluted 10-3 vol/vol).  Cell-free supernatants were then har- 
vested, filtered, and stored at  -80~  until assayed for cytokines. 
Mock- and HIV-infected monocytes were washed and stimulated 
with S.  aureus for 24 h.  Cell-free supernatants  were harvested, 
filtered, and stored at  -80~  until  assayed. 
Cytokine Assays.  The production  of Ib12 p40 (either alone or 
associated with p35) was measured by specific RIA using the mAb 
pair Cll.79/C8.6 (sensitivity, 10 pg/ml) as described (4). Biologi- 
cally active I1.12 p70 was quantitated using a newly developed Ab 
capture bioassay (sensitivity, 10 pg/ml) as described by D'Andrea 
et al. (13). TNF-cz and II-1/3 were determined by ILIA using mAbs 
B154.7/B154.9 and F18.609/F18.206  (kindly provided by M.A. 
Cousin, Roussel Uclaf, ILomainville, France), respectively. All de- 
terminations were done in triplicate. I1-4, IL-6, and I1-10 were quan- 
titated using commercially available specific ELISA assays (Quan- 
tikine, R & D Systems, Inc., Minneapolis, MN for I1-4; Biosource 
International,  Camarillo, CA for Ib6 and Ibl0). In indicated ex- 
periments, PBMC were stimulated with S. aureus in the presence 
of optimal concentrations of neutralizing anti-IL-10 mAb 191:1 (10 
#g/m1,  kindly provided by K. Moore, DNAX, Palo Alto, CA). 
Results and Discussion 
We have previously reported that  short-term  incubation 
of lymphocytes from HIV-infected patients with IL-12 re- 
stored the NK cell cytotoxic activity to levels mediated by 
unstimulated PBMC of healthy donors (5). IL-12 also stimu- 
lated IFN-3/production by lymphocytes of HIV-infected pa- 
tients, although their ability to produce IFN-3' in response 
to both IL-12 and other inducers was reduced compared with 
lymphocytes from healthy seronegative controls (5). Further- 
more, we have reported enhancement of NK cell-mediated 
cytotoxicity against herpesvirus (CMV, varicella Zoster virus, 
HSV) and HIV-infected target cells with concentrations of 
IL-12 "~100- 1,000-fold lower than concentrations oflFN-cr 
IFN-~,  and IL-2 required for a similar effect (14).  It is in- 
teresting to note that Clerici et al. (15) recently demonstrated 
that in vitro addition of IL-12 to HIV-infected individuals 
can restore HIV-specific IL-2 and IFN-? production as well 
as antigen-specific lymphocyte proliferation. 
In the present study, PBMC from 73 adult HIV-seropositive 
individuals at different stages of disease,  stimulated in vitro 
with the common human pathogen S. aureus (heat fixed) for 
24 h, produced 10-fold less IL-12 p40 chain on average than 
cells from healthy control donors (Fig. 1 A). Statistical anal- 
ysis of IL-12 p40 production in the 73 patients grouped ac- 
cording to absolute CD4 + cell count revealed  significantly 
less IL-12 p40 production for each group as compared with 
controls  (Student's  t  test, p  <0.001).  p40  production  by 
PBMC  of  asymptomatic  individuals  with  >500  CD4 + 
cells/ram 3 was not significantly different from that of AIDS 
patients with <200 CD4 +/mm 3. Unlike S. aureus-induced 
p40 production, low constitutive production of p40 detected 
in unstimulated cultures was not statistically different for con- 
trois (58  _+  10 pg/ml, n  =  61) and patients (54  +  9 pg/ml, 
n  =  73). The ability of normal donors and patients to pro- 
duce IL-12 p70 in response to S.  aureus was determined in 
32 patients.  Control donors produced fivefold more IL-12 
p70, on average,  in response to S. aureus than did the HIV- 
infected patients  tested (Fig.  1 B, p  <0.001).  For the same 
group of HIV-infected and control donors, the difference in 
IL-12 p40 production in response to S. aureus was ,v20-fold. 
Therefore,  although  the  PBMC  from  the  patients  were 
significantly and severely depressed in their ability to pro- 
duce biologically active IL-12, this defect was not as severe 
as that involving the production of p40. This partial dissoci- 
ation in the ability to produce p40 and p70 might  depend 
on the state of activation of monocyte/macrophages in HIV- 
infected individuals. In contrast, production of TNF-ot and 
IL-1B (under the same culture conditions) was equivalent for 
PBMC from patients and control donors (Fig.  1, C and/9). 
In  addition,  PBMC from HIV-infected patients  produced 
three-  to fourfold more IL-6 both constitutively (data not 
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Figure  1.  Ib12,  TNF-,v,  IL-I~, and Ib6 
production in response  to &  aureus.  PBMC 
from 73 HIV-seropositive patients divided into 
three  groups  according  to  their  CD4  cell 
counts,  and  from healthy  HIV-seronegative 
donors were cultured for  24  h  in complete 
medium in the presence of heat-inactivated $. 
aureus. Cytokine production was measured in 
the cell-free  supernatants.  (A) II,12 p40 was 
measured  by  ILIA  using  the  mAb  pair 
Cll.79/C8.6.  (B) Biologically active I1.,12 p70 
was quantitat~l using an Ab capture bioassay. 
(C) TNF-a (42 patients, 28 controls) and (D) 
Ibl/~  (28 patients,  26 controls) were deter- 
mined by ILIA. (E) IL-6 (20 patients,  15 con- 
trols)  was  quantitated  by  ELISA.  Control 
healthy  donors  (O)  and  HIV-seropositive 
donors  (O)  represent  results  for  individual 
donors. Horizontal bars indicate mean _+ SE. 
shown, p <0.001) and after S.  aureus stimulation than con- 
trol  donors (Fig.  1 E, p  <0.001).  These data suggest that 
the defect in IL-12 production by PBMC of HIV-infected 
patients is relatively specific and not secondary to a general- 
ized inability of their  monocytes to produce  cytokines. 
IL-10, a cytokine produced by various cell types including 
monocytes, B and T cells, acts at both the accessory and T 
cell levels to inhibit Thl-like functions such as cytokine produc- 
tion and proliferation.  IL-10 also efficiently  inhibits IL-12 
production  (13).  Because  IL-10  has been suggested to be 
produced at elevated levels in HIV-infected patients (16), we 
investigated  whether the decreased ability of PBMC from 
HIV-infected patients to produce IL-12 might be secondary 
to enhanced production of IL-10. Analysis of IL-10 produc- 
tion by PBMC in response to S. aureus stimulation revealed 
no significant difference between HIV-infected patients and 
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Figure  2.  I1-,10  production and effect of endogenous 11.,10 on IL-12 p40 
production. (+4) An ELISA assay was used to measure II,,10 in superna- 
tants  of 24-h  cultures  of PBMC  from healthy controls  (O)  or HIV- 
seropositive patients  (O) in the presence of S.  aureus.  (B)  PBMC from 
healthy controls and patients  were stimulated for 24 h with S. aureus in 
the presence of neutralizing anti-IL-10 mAb 19F1, and IL-12 p40 was mea- 
sured in cell-free  supernatants  by RIA. 
control donors (Fig.  2 A), in fact controls produced  more 
IL-IO than patients (5,515 pg/ml vs. 3,267 pg/ml), although 
this difference was not statistically different.  In the absence 
of stimulation, a low spontaneous production of IL-IO was 
detected by cells from controls and patients  (NS, data not 
shown). Addition of neutralizing anti-IL-10 mAb to the cul- 
tures at concentrations  sufficient  to inhibit the IL-IO pro- 
duced in response  to S.  aureus,  enhanced  IL-12 production 
in PBMC cultures of HIV-infected patients  (636 pg/ml vs. 
267 pg/ml, t =  1,898, NS) and control donors (3,258 pg/ml 
vs. 1,986 pg/ml, t  =  3.408, p  =  0.011, Fig. 2 B). Addition 
of exogenous IL-10 to patients'  PBMC cultures  induced a 
dose-dependent  decrease in IL-12 production to undetectable 
levels (data not shown), similar to results obtained with normal 
donors (13 and data not shown). Thus IL-IO induced by S. 
aureus stimulation has an autocrine-negative  feedback on IL- 
12 production, and neutralization  of IL-IO enhances  IL-12 
production.  However,  this  relative  enhancement was not 
significantly different for HIV-infected patients and control 
donors (1.8  +  0.36-fold vs.  1.93  _+  0.23-fold,  t  =  1.291, 
NS), indicating that production of IL-10 in vitro during S. 
aureus stimulation is not responsible for the fact that PBMC 
from HIV-infected patients produce less IL-12 than those from 
uninfected donors. Although continuous exposure of mono- 
cytes to elevated levels of IL-IO in vivo, proposed  to be pro- 
duced in the later stages of HIV infection (16), might impair 
their ability to produce IL-12, this possibility seems unlikely 
because IL-10 also inhibits production of TNF-c~ and IL-1/3 
(13), making it difficult to explain the specific defect in IL-12 
production. 
IL-4, reported to be overproduced by T cells of HIV-infected 
patients at intermediate to late stages of the disease (17), also 
moderately  inhibits IL-12 production when present during 
monocyte stimulation (8). However, IL-4 was not produced 
at detectable levels (<30 pg/ml, 24 patients and 36 controls) 
by PBMC from control donors or patients  stimulated by S. 
aureus. Although IL-4 was reported to be overproduced by 
HIV-seropositive donors at least at certain stages of the dis- 
ease (17),  we observed  that stimulation by phorbol-diester 
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by PBMC from control donors, than from a small number 
of HIV-infected individuals tested (data not shown). Further- 
more, IL-4--mediated inhibition of cytokine production is not 
selective for IL-12, and pretreatment of PBMC and mono- 
cytes from control donors with IL-4 stimulates rather than 
inhibits IL-12 production (D'Andrea, A. and G. Trinchieri, 
manuscript in preparation). Thus IL-4 is an unlikely candi- 
date for causing the sdective defect in IL-12 production ob- 
served in most HIV-infected individuals at all stages of disease. 
To determine whether the defect in IL-12 production in 
HIV-infected patients was dependent on HIV infection, we 
tested the effect of in vitro infection of monocytes with HIV 
on their ability to produce IL-12 in response to S.  aureus. 
Monocytes freshly isolated from six different healthy seronega- 
tive donors were infected with the duotropic strain 89.6, as 
well as  with  the lymphotropic strains  IIIB  and MN  for 
5-7 d.  89.6-infection of monocytes was confirmed by p24 
Ag determinations (2-5 ng/ml, Fig. 3, right). Monocytes in- 
oculated with IIIB, MN, or with heat-inactivated 89.6 pro- 
duced negligible amounts of p24 Ag (data not shown). After 
stimulation with S. aureus for 24 h, 89.6-infected monocytes 
produced significantly less  IL-12  p40  than  mock-infected 
monocytes (Fig. 3, center, p  <0.001). In contrast, monocytes 
inoculated with lymphocyte-tropic strains IIIB and MN, as 
well as monocytes inoculated with heat-inactivated 89.6, pro- 
duced levels of IL-12  similar to those produced by mock- 
infected monocytes (data not shown). Similarly, in vitro in- 
fection of fresh monocytes had no significant effect on their 
ability to produce IL-10 in response to S. aureus (Fig. 3, left, 
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Figure 3.  Modulation  of I1.-12 p40 and IL-10 production in response 
to S. aureus after in vitro HIV infection  of monocytes.  Monocytes  pre- 
pared as described  in Materials and Methods, were mock infected  or in- 
fected  with cell-free  HIV-1 monocyte-tropic  strain 89.6 (20-30 ng/ml p24 
Ag) for 4 h. After 5-7 d, cells  were  washed  and stimulated  with S. aureus 
for 24 h. Cell-free  supernatant fluids were harvested  and IL-10 (left) and 
I1.-12 p40 (center) determined  by ELISA and ILIA, respectively,  p24 Ag 
concentration  was measured  by ELISA (r/ght). Each symbol type refers 
to a single  donor. The six donors for II.-12 p40 production are representa- 
tive of over 15 total different  donors tested, with similar results. 
3,004 pg/ml by uninfected monocytes vs. 2,112 pg/ml in in- 
fected monocytes; NS), although IL-12 p40 production was 
significantly reduced (Fig. 3, center). These data suggest that 
in vitro infection of the monocytes and not simple exposure 
to the virus is required for IL-12  inhibition. 
The presence of inhibitory cytokines in the virus prepara- 
tions used was a possible concern in the interpretation of results 
with HIV exposed monocytes. IL-4 could not be detected 
in any of the virus preparations and culture supernatants used 
for mock infection, whereas IL-10 concentrations were 434 
pg/ml in supernatants of CEM-X174 calls, and 90 pg/ml in 
supernatants of 89.6-infected CEM-X174 cells. Although these 
concentrations of IL-10 could be responsible for a partial in- 
hibition of IL-12 production if present at all times during 
the culture, IL-12 production was not inhibited under the 
experimental condition used, since mock-infected monocytes 
produced higher levels of IL-12 than 89.6-infected monocytes. 
The in vitro results are consistent with the hypothesis that 
impaired IL-12 production is dependent on HIV infection 
and not  secondary to  altered immunoregnlation or other 
infection-associated factors.  However, only a minor propor- 
tion of the circulating monocytes of HIV-infected individ- 
uals harbors HIV (1, 2), and in the cultured monocytes in 
vitro infected with HIV, only a proportion of cells (~10% 
as detected by immunofluorescence using serum from HIV- 
infected patients) reacted positively at the time of stimula- 
tion with S.  aureus.  Thus, it is possible that HIV infection 
may not directly downregulate IL-12 production, but acts 
indirectly through viral or cellular products, possibly including 
immunoregnlatory cytokines, thus the exact molecular mech- 
anism involved remains unclear at the present time. 
Our data indicate that PBMC from HIV-infected individ- 
uals, even at early stages of the disease when no symptoms 
are present and the number of CD4 + ceils is still close to 
normal levels, are severely impaired in their ability to pro- 
duce IL-12 in response to S. aureus. Because we analyzed only 
cells from peripheral blood, and relatively little is known about 
the major IL-12 producer ceils in vivo, it is possible that the 
defect in IL-12 production is not generalized and that IL-12, 
at least at early stages of the disease, is still produced at suffident 
levels from other tissues. Alternatively, a very early infection- 
associated  deficiency in IL-12 production may not result in 
an observable pathologic deficiency in the immune response 
until the decrease in the number of CD4 + cells and of other 
immune parameters in the symptomatic stages of the disease 
makes optimal levels of this cytokine necessary for efficient 
resistance to infection or neoplastic growth. Several previous 
findings in all or most HIV-infected patients are compatible 
with a defect in IL-12 production, in particular,  early deficien- 
cies in T  cell proliferative responses to antigens (18) and in 
production of IFN-qr  (19, 20), defective NK cell-mediated 
cytotoxic activity (21), and B cell activation with hyper-IgE 
production (1,  2). 
It has been proposed that HIV-infected patients have an 
in vitro imbalance of the Thl/Th2 responses,  with severely 
depressed Thl response and enhanced Th2 response (16, 17, 
22,  23).  Whereas these latter studies described an in vitro 
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from HIV-infected patients, this phenomenon does not ap- 
pear to occur in lymphoid tissue from patients (24). Several 
factors, from in vivo anatomic locations to in vitro culture 
conditions, can influence the pattern of cytokine expression, 
and might  explain these disparate results. 
Our recent findings indicate that the major effect of IL-12 
on Thl cell generation is exerted through the induction of 
a stable priming of IFN-'y for efficient production from Thl 
or Th0 cells (producing both IFN-3' and IL-4) (25). In the 
absence of IL-12, low production of IFN-3' might mask the 
detection of an efficient Thl response, whereas a Th0 response 
would be characterized by low IFN-3' and high IL-4 produc- 
tion,  mimicking  the  phenotype  of a  Th2-type  response 
(17,  19). 
In experimental  animals,  IL-12 has been shown to have 
a protective effect in vivo against infection with Toxoplasma 
gondii,  an opportunistic parasite in some AIDS patients (9). 
A curative effect of IL-12 in vivo has also been observed in 
susceptible BALB/c mice infected with Leishmania major (10). 
Because the susceptibility of BALB/c mice to this parasite 
is due to a predominant  Th2 response rather than the Thl 
response observed in resistant  strains,  Leishmania infection 
has been proposed as a possible model for immune responses 
in AIDS patients, in which a predominant Th2 response has 
been postulated (22). It is also of interest that IL-12 acts as 
a potent adjuvant in vaccination with L. major soluble Ags 
in BALB/c mice, inducing a Thl memory immune response 
and persistent resistance to infection (26). Thus,  IL-12 is a 
potential adjuvant in vaccination for those infectious organisms, 
including possibly HIV, against which a potent cellular im- 
mtmity in parallel with a humoral response may provide com- 
plete protection. Even though IL-12 has no direct antiviral 
effect, this cytokine might  be considered a potential  ther- 
apeutic agent in HIV-infected patients,  to correct immune 
defects (5, 15), and to augment resistance mechanisms against 
opportunistic  infections  and tumor  growth. 
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